학술논문
Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning
Document Type
article
Author
Elisabeth Bumes; Claudia Fellner; Franz A. Fellner; Karin Fleischanderl; Martina Häckl; Stefan Lenz; Ralf Linker; Tim Mirus; Peter J. Oefner; Christian Paar; Martin Andreas Proescholdt; Markus J. Riemenschneider; Katharina Rosengarth; Serge Weis; Christina Wendl; Sibylle Wimmer; Peter Hau; Wolfram Gronwald; Markus Hutterer
Source
Cancers, Vol 14, Iss 11, p 2762 (2022)
Subject
Language
English
ISSN
2072-6694
Abstract
The isocitrate dehydrogenase (IDH) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of IDH mutation status is desirable in cases where tumor biopsy is not possible and for monitoring neuro-oncological therapies. In a previous publication, we presented reliable prediction of IDH mutation status employing proton magnetic resonance spectroscopy (1H-MRS) on a 3.0 Tesla (T) scanner and machine learning in a prospective cohort of 34 glioma patients. Here, we validated this approach in an independent cohort of 67 patients, for which 1H-MR spectra were acquired at 1.5 T between 2002 and 2007, using the same data analysis approach. Despite different technical conditions, a sensitivity of 82.6% (95% CI, 61.2–95.1%) and a specificity of 72.7% (95% CI, 57.2–85.0%) could be achieved. We concluded that our 1H-MRS based approach can be established in a routine clinical setting with affordable effort and time, independent of technical conditions employed. Therefore, the method provides a non-invasive tool for determining IDH status that is well-applicable in an everyday clinical setting.